TELLGEN CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.84 CNY | +8.26% |
|
-8.02% | -27.25% |
| Sales 2021 | 655M 90.48M | Sales 2022 | 716M 98.96M | Capitalization | 3.38B 468M |
|---|---|---|---|---|---|
| Net income 2021 | 161M 22.25M | Net income 2022 | 125M 17.28M | EV / Sales 2021 | 7.23 x |
| Net cash position 2021 | 467M 64.49M | Net cash position 2022 | 538M 74.31M | EV / Sales 2022 | 3.98 x |
| P/E ratio 2021 |
32.4
x | P/E ratio 2022 |
27.1
x | Employees | 710 |
| Yield 2021 |
0.79% | Yield 2022 |
0.96% | Free-Float | 64.74% |
More Fundamentals
* Assessed data
More news
| 1 day | +8.26% | ||
| 1 week | -8.02% | ||
| Current month | -8.42% | ||
| 1 month | -7.16% | ||
| 3 months | -21.66% | ||
| 6 months | -32.85% | ||
| Current year | -27.25% |
1 week
11.86
14.08
1 month
11.8615.60
Current year
9.9418.02
1 year
9.9424.07
3 years
9.9450.25
5 years
9.9450.25
10 years
9.9450.25
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Er Yao
CEO | Chief Executive Officer | 54 | 03-11-05 |
Xiao Qing Wang
BRD | Director/Board Member | 45 | 09-07-31 |
En Huan Yang
BRD | Director/Board Member | 42 | 09-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Er Yao
CEO | Chief Executive Officer | 54 | 03-11-05 |
Zhang Fu Yu
BRD | Director/Board Member | 61 | 19-08-13 |
En Huan Yang
BRD | Director/Board Member | 42 | 09-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 12.84 | +8.26% | 2,355,184 |
| 24-04-16 | 11.86 | -7.92% | 2,157,220 |
| 24-04-15 | 12.88 | -5.78% | 2,562,550 |
| 24-04-12 | 13.67 | -1.51% | 1,171,070 |
| 24-04-11 | 13.88 | -0.57% | 1,449,350 |
End-of-day quote Shenzhen S.E., April 16, 2024
More quotes
Tellgen Corp is a company engaged in research, development, production and sales of in vitro diagnostic reagents and instruments. The Company's products are comprised of immunodiagnostic products, molecular diagnostic products and biochemical diagnostic products, including tumor marker detection products, human papillomavirus (HPV) nucleic acid testing products, autoimmune disease detection products and lung cancer methylation mutation detection products.
Calendar
2024-04-22
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -27.25% | 289M | |
| -0.50% | 12.58B | |
| -19.65% | 6.82B | |
| -2.87% | 5.14B | |
| -7.82% | 4.22B | |
| -0.84% | 4.21B | |
| -47.89% | 3.47B | |
| +8.57% | 2.65B | |
| -6.37% | 2.25B | |
| -2.61% | 1.69B |
- Stock Market
- Equities
- 300642 Stock
